Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2001 1
2002 4
2005 2
2006 3
2007 2
2008 3
2009 2
2010 5
2012 2
2013 3
2014 5
2015 12
2016 8
2017 12
2018 10
2019 9
2020 12
2021 13
2022 6
2023 12
2024 8
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier A, D'Argenio M, Bonmati C, Billio A, Lejeune C, Scappini B, Pigneux A, Zappasodi P, Recher C, Grimaldi F, Ades L, Lemoli RM. Cluzeau T, et al. Among authors: gottardi m. Blood Adv. 2025 Feb 25;9(4):752-758. doi: 10.1182/bloodadvances.2024014279. Blood Adv. 2025. PMID: 39454204 Free PMC article.
Imatinib and hyperlipidemia.
Gottardi M, Manzato E, Gherlinzoni F. Gottardi M, et al. N Engl J Med. 2005 Dec 22;353(25):2722-3. doi: 10.1056/NEJMc052500. N Engl J Med. 2005. PMID: 16371644 No abstract available.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group. Todisco E, et al. Among authors: gottardi m. Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24. Cancer. 2023. PMID: 36692409 Free article.
Editorial: Inflammation and blood diseases, a dog chasing its tail.
Cumbo C, Tarantini F, Gottardi M, Albano F. Cumbo C, et al. Among authors: gottardi m. Front Oncol. 2023 Mar 24;13:1180559. doi: 10.3389/fonc.2023.1180559. eCollection 2023. Front Oncol. 2023. PMID: 37035144 Free PMC article. No abstract available.
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy.
Mosna F, Borlenghi E, Litzow M, Byrd JC, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan EA, Gurrieri C, Yeung CCS, Deeg HJ, Capelli D, Candoni A, Gotlib JR, Lunghi M, Pullarkat S, Lanza F, Galimberti S, Forghieri F, Venditti A, Festuccia M, Audisio E, Marvalle D, Rigolin GM, Roti G, DiBona E, Visani G, Albano F, Eisfeld AK, Valent P, Huls G, Borthakur G, Krampera M, Martinelli G, Kröger N, Sperotto A, Gottardi M. Mosna F, et al. Among authors: gottardi m. Haematologica. 2025 Mar 1;110(3):608-620. doi: 10.3324/haematol.2024.285448. Haematologica. 2025. PMID: 39385741 Free PMC article.
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Papayannidis C, Petracci E, Zappasodi P, Fracchiolla N, Ciceri F, Sartor C, Roncoroni E, Di Raimondo F, Mattei D, Giannini MB, Lanza F, Gottardi M, Del Principe MI, Borlenghi E, Fumagalli M, Vallisa D, Sica S, Di Renzo N, Fabbiano F, Todisco E, de Fabritiis P, Luppi M, Passamonti F, Corradini P, Petruzziello F, Pane F, Ferrara F, Mambelli G, Volpi R, Frabetti F, Zingaretti C, Marconi G, Martinelli G. Papayannidis C, et al. Among authors: gottardi m. Cancer. 2025 Apr 1;131(7):e35820. doi: 10.1002/cncr.35820. Cancer. 2025. PMID: 40120068 Free PMC article.
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study.
Fianchi L, Piciocchi A, Guolo F, Marchesi F, Marsili G, Cattaneo C, Gottardi M, Restuccia F, Candoni A, Ortu La Barbera E, Fazzi R, Pasciolla C, Finizio O, Fracchiolla N, Delia M, Lessi F, Dargenio M, Bonuomo V, Del Principe MI, Zappasodi P, Picardi M, Basilico C, Piedimonte M, Minetto P, Chiusolo P, Prezioso L, Buquicchio C, Melillo L, Zama D, Farina F, Mancini V, Rondoni M, Busca A, Pagano L. Fianchi L, et al. Among authors: gottardi m. Ann Hematol. 2025 May;104(5):2731-2736. doi: 10.1007/s00277-025-06381-3. Epub 2025 May 24. Ann Hematol. 2025. PMID: 40411596 Free PMC article.
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.
Ghelli Luserna di Rorà A, Jandoubi M, Padella A, Ferrari A, Marranci A, Mazzotti C, Olimpico F, Ghetti M, Ledda L, Bochicchio MT, Paganelli M, Zanoni M, Cafaro A, Servili C, Galimberti S, Gottardi M, Rondoni M, Endri M, Onofrillo D, Audisio E, Marconi G, Simonetti G, Martinelli G. Ghelli Luserna di Rorà A, et al. Among authors: gottardi m. J Transl Med. 2024 Nov 26;22(1):1062. doi: 10.1186/s12967-024-05838-9. J Transl Med. 2024. PMID: 39587643 Free PMC article.
129 results